World ADC 2023 – targeting the folate receptor rises from the ashes
Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.
JP Morgan 2023 – Sutro makes its pitch to beat Immunogen
The group reckons it can target twice as many ovarian cancer patients, but an important disclosure shows that its case it not clear-cut.
Not so fast for some accelerated approvals
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Immunogen’s Mirasol trial goes down to the wire
Full data from mirvetuximab’s Soraya study make investors nervous as readout of the Mirasol confirmatory trial looms.
Sutro’s folate challenge to Immunogen hits a problem
In a battle of anti-folate receptor α projects STRO-002 outperforms mirvetuximab, but Sutro investors are not celebrating.
Biopharma developments over the Christmas period
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.